Peer-reviewed veterinary case report
Doxorubicin treatment results for histiocytic sarcoma in 31 dogs
By Doka, Rhiannon M et al.·Published in Journal of the American Veterinary Medical Association·2022·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003-2017).
- Species:
- dog
Plain-English summary
A group of 31 dogs diagnosed with histiocytic sarcoma, a type of cancer, were treated with doxorubicin, either alone or alongside surgery or radiation. The treatment showed a modest success rate, with only 26% of the dogs responding positively. For those with localized tumors, the response rate was better at 43%, while it was lower at 21% for dogs with more widespread disease. On average, dogs lived about 169 days after diagnosis, with some experiencing a delay in tumor progression. While doxorubicin can help, the overall benefits are limited compared to other treatment options.
People also search for: dog histiocytic sarcoma treatment · doxorubicin for dogs cancer · dog cancer survival rates
Abstract
OBJECTIVE: To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy. ANIMALS: 31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017. PROCEDURES: Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests. RESULTS: The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy. CLINICAL RELEVANCE: Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36054007/